

Freedom of Information Request: Our Reference CTMUHB_79_22

You asked:

1. How many patients have been treated with the following drugs in the past 4 months:

- **Erenumab (Aimovig) - any disease**
- **Fremanezumab (Ajovy) - any disease**
- **Galcanezumab (Emgality) - any disease**
- **Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY**

Please find below, tables populated with the data captured on our Medicine Management system for the period October 21 to January 22.

Medicine	Number of Patients
Erenumab (Aimovig) - any disease	5
Fremanezumab (Ajovy) - any disease	16
Galcanezumab (Emgality) - any disease	**

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Please note that we are unable to provide the number of patients treated with Botulinum Toxin as this is not captured centrally. However, we have provided data on the number of vials issued.

Medicine	Strength	Number of Vials
Botulinum Toxin - Botox	50mg	52
Botulinum Toxin - Botox	100mg	73
Botulinum Toxin - Botox	200mg	39
Botulinum Toxin - Dysport	300mg	9
Botulinum Toxin - Dysport	500mg	10
Botulinum Toxin - Xeomin	50 units	10
Botulinum Toxin - Xeomin	100 units	3

2. I would like to understand the source of funding of Botox and anti-CGRP monoclonal antibody treatments (Ajoovy, Aimovig, Emgality) for migraine. Could you please answer the following questions:

- Does the Health Board commission/fund Botulinum Toxin treatment for migraine (Y/N)?**

Yes.

- Does the Health Board commission/fund anti-CGRP treatments for migraine (Y/N)?**

Yes

- In case the Health Board actively provides Botulinum Toxin treatment for migraine but does not commission/fund it, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your Health Board.**

N/A.

- In case the Health Board actively provides anti-CGRP treatments for migraine but does not commission/fund them, then please provide the name(s) of the other NHS organisations that commission/fund these treatments at your trust.**

N/A.